A new report predicts that the market for hidradenitis suppurativa (HS) treatments will grow significantly over the next decade, from $1.84 billion in 2024 to $7.83 billion by 2034. This growth is driven by the development of new, more effective medications that target different inflammation pathways in the body. Currently, only three biologic drugs are approved for HS: Humira (adalimumab), Cosentyx (secukinumab), and Bimzelx (bimekizumab). While Humira was the first approved treatment, it has limited effectiveness, with only about 25–30% of patients responding well. The newer drugs, like Bimzelx, have shown much better results in clinical trials, with up to 64% of patients seeing improvement. However, these treatments can be expensive and may have side effects, such as fungal infections. Several promising new drugs are in development, including sonelokimab, which targets inflammation more deeply in the skin, and povorcitinib, which may help reduce pain and improve quality of life. Experts believe these new treatments could reshape how HS is managed, especially if they can be used earlier in the disease. A major challenge in HS care is that many patients go undiagnosed for years, leading to severe damage by the time they receive treatment. Current therapies mostly help moderate to severe cases, leaving early-stage patients with few options. The U.S. is expected to lead market growth due to a larger number of diagnosed patients and better access to biologic treatments. However, challenges like safety concerns, competition among new drugs, and insurance coverage issues may slow progress. With nearly 33 new treatments in development, the future of HS care looks promising, offering hope for better, more personalized treatment options for patients.